NR4A1 and cancer: Many conventional small molecular ligands including 1,1-bis(3′-indolyl)-1-(p-hydroxyphenyl) methane (DIM-C-pPhOH), kaempferol, quercetin, CCE9, celastrol, etc., have been identified as inhibitors of NR4A1 that can impact both tumor intrinsic and extrinsic cancer immune responses [66,67,68,69].